ANAPTYSBIO INC
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
ANAB$48.38+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share data)
| Year EndedDecember 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Collaboration revenue | $17,157 | $10,287 | $63,175 |
| Operating expenses: | |||
| Research and development | 132,283 | 88,798 | 98,496 |
| General and administrative | 41,946 | 36,643 | 21,493 |
| Acquired in-process research and development | 7,339 | — | — |
| Total operating expenses | 181,568 | 125,441 | 119,989 |
| Loss from operations | (164,411) | (115,154) | (56,814) |
| Other income (expense), net: | |||
| Interest income | 18,873 | 7,550 | 431 |
| Non-cash interest expense for the sale of future royalties | (18,083) | (21,108) | (1,450) |
| Other (expense) income, net | (2) | 12 | 37 |
| Total other income (expense), net | 788 | (13,546) | (982) |
| Loss before income taxes | (163,623) | (128,700) | (57,796) |
| Benefit (Provision) for income taxes | 4 | (24) | — |
| Net loss | (163,619) | (128,724) | (57,796) |
| Other comprehensive loss: | |||
| Unrealized gain (loss) on available for sale securities | 4,449 | (4,824) | (418) |
| Comprehensive loss | $(159,170) | $(133,548) | $(58,214) |
| Net loss per common share: | |||
| Basic and diluted | $(6.08) | $(4.57) | $(2.11) |
| Weighted-average number of shares outstanding: | |||
| Basic and diluted | 26,924 | 28,165 | 27,431 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.